Samsung Biologics named Champion in 2020 CMO Leadership Awards
SONGDO, South Korea, April 8, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) announced that it has been awarded the 2020 CMO Leadership Awards for its excellence in the Capabilities, Compatibility, Quality, Reliability, and Service categories across Big Pharma and Overall (combined Big and Sm...
Samsung Biologics enters into a development and manufacturing partnership with PharmAbcine for oncology and neovascular treatment
SONGDO, South Korea, April 5, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) entered into a strategic partnership with PharmAbcine for the development and manufacturing of PMC-402 pipeline, a next generation therapeutic antibody candidate to treat oncology and neovascular disorders. Under th...
Samsung Biologics expands leadership for CDO business
SONGDO, South Korea, March 30, 2020 /PRNewswire/ -- Samsung Biologics
(207940.KS) has appointedEun Young Yang as vice president of business
development for the company's expanded CDO (contract development organization)
business.
Samsung Biologics Adds Greater Expertise and Diversity to Its Board
SONGDO, South Korea, March 20, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) announced the appointment and expansion of its board of directors at its 9th annual general meeting of shareholders that took place on March 20th . In the course of expanding its business model from a contract manufa...
Samsung Biologics expands presence in Greater China Region with CDO partnership for Alzheimer's candidate
SONGDO, South Korea, March 16, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) entered into a contract development and manufacturing agreement with APRINOIA Therapeutics to develop an anti-tau monoclonal antibody candidate to treat primary and secondary tauopathies, including Progressive Supr...
Samsung Biologics and STCube Enter into Development and Manufacturing Agreement for Novel Target Anticancer Drug
SONGDO, South Korea, March 2, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and STCube announced a strategic development and manufacturing service agreement for STT-003 antibody, an anti-cancer drug candidate. Under the agreement, Samsung Biologics will offer a wide range of services from c...
Samsung Biologics Confirms 'No Impact' of COVID-19 with Business Continuity Plan in Effect
SONGDO, South Korea, Feb. 24, 2020 /PRNewswire/ -- Samsung Biologics has been monitoring the COVID-19 situation closely since the initial outbreak in late January and taking proactive measures company-wide to ensure a safe working environment and continuous business operations. The company confi...
